

FORM D

03006441

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D.

1115285

3235-0076				
3233-0070				
ay 30, 2005				
hours per response1.00				

SEC USE ONLY

SECTION 4(6), AND/OR	Prefix Serial
UNIFORM LIMITED OFFERING EXEMPTION	DATE RECEIVED
Name of Offering (check if this is an amendment and name has changed, and indicate change.)	PECEIVED
Series D Preferred Stock	
Filing Under (Check box(es) that apply): □ Rule 504 □ Rule 505 ■ Rule 506 □ Sector Type of Filing: □ New Filing □ Amendment	rtion 4(6) □ ULOE FEB 2 0 2003
A. BASIC IDENTIFICATION DA	ATA 207
Enter the information requested about the issuer	
Name of Issuer (□ check if this is an amendment and name has changed, and indicate change.)	
Eyetech Pharmaceuticals, Inc.	
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
500 Seventh Avenue, 18th Floor, New York, NY 10018	212-997-9241
Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) different from Executive Offices)	Telephone Number (Including Area Code)
Brief Description of Business:	
A biopharmaceutical company formed to discover, develop and commercialize new drugs to red	luce and prevent vision loss
Type of Business Organization	other (please specify): Description of the process of the proce
■ corporation □ limited partnership, already formed	□ other (please specify):
□ business trust □ limited partnership, to be formed	
Month Year Actual or Estimated Date of Incorporation or Organization 02 00 ■ Actual □ Estimate Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for St	tate: FINANCIAI
CN for Canada: FN for other foreign jurisdicti	non) DE

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

CN for Canada; FN for other foreign jurisdiction)

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATT	ENT	NOL
ALL	DIN I	ION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notical will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

	A. BASIC IDEN	TIFICATION DATA		
Enter the information requested for the follow Each promoter of the issuer, if the issuer Each beneficial owner having the power Each executive officer and director of co Each general and managing partner of partners.	has been organized within the to vote or dispose, or direct the reporate issuers and of corporat	e vote or disposition of, 10		
Check Box(es) that Apply: □ Prom	oter Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)				
Guyer, David R.				
	r and Street, City, State, Zip C	ode)		
of Protect Discourse d'arts Inc. 500 Council A	oth was a No. 1	NTV 10010		
c/o Eyetech Pharmaceuticals, Inc., 500 Seventh A Check Box(es) that Apply: □ Prom		Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	oter beneficial Owner	Executive Officer	a Director	Ochera and of Managing Lattice
Sblendorio, Glenn Business or Residence Address (Number	r and Street, City, State, Zip C	ode)		
		·		
Charles Pay(22) that Apply				
Check Box(es) that Apply: Prom Full Name (Last name first, if individual)	oter	■ Executive Officer	□ Director	☐ General and/or Managing Partner
run Name (Last name mst, ii morviduai)				
Adamis, Anthony			~	
Business or Residence Address (Number	and Street, City, State, Zip Co	ode)		
c/o Eyetech Pharmaceuticals, Inc., 500 Seventh A	venue, 18th Floor, New York	, NY 10018		
Check Box(es) that Apply: □ Prom	oter Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)				
McLaughlin, John				
Business or Residence Address (Number	and Street, City, State, Zip Co	ode)		
c/o Eyetech Pharmaceuticals, Inc., 500 Seventh A	venue, 18 th Floor, New York	. NY 10018		
Check Box(es) that Apply:		☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)				
Akkaraju, Srinivas				
	r and Street, City, State, Zip C	ode)		
c/o Eyetech Pharmaceuticals, Inc., 500 Seventh A	10th Place Nam Vanla	NIX/ 10010		
Check Box(es) that Apply:		□ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	Delicited Owner	Executive Officer	2 Breetor	a denotal analog Managing Paralog
CP L M C				
Glick, Martin Business or Residence Address (Number	r and Street, City, State, Zip Co	ode)		
	•	•		
c/o Eyetech Pharmaceuticals, Inc., 500 Seventh A Check Box(es) that Apply:				
Check Box(es) that Apply:	oter	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Tun Ivanie (Last name mist, it morvioual)				
Mullen, Michael	10, 0', 0, 7', 0			
Business or Residence Address (Number	er and Street, City, State, Zip C	.ode)		
c/o Eyetech Pharmaceuticals, Inc., 500 Seventh A	venue, 18th Floor, New York	NY 10018		
Check Box(es) that Apply: ☐ Prom	oter Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)				
Patel, Samir				
Business or Residence Address (Number	er and Street, City, State, Zip C	Code)		
c/o Eyetech Pharmaceuticals, Inc., 500 Seventh A	venue, 18th Floor, New York	, NY 10018		

		A RASIC IDENT	TIFICATION DATA		
		A. BASIC IDENT	—————		
Enter the information requested forEach promoter of the issuer, it		een organized within the	past five years;		
 Each beneficial owner having 	the power to vot	e or dispose, or direct the	vote or disposition of, 10	% or more of a c	lass of equity securities of the issuer;
 Each executive officer and dir Each general and managing part 			e general and managing pa	artners of partners	ship issuers; and
		<u> </u>			
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual))				
Penhoet, Ed					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
c/o Eyetech Pharmaceuticals, Inc., 500	Seventh Avenue	e 18 th Floor New York	NV 10018		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		- Beneficial Owner	L'Accutive Officer	Director	a ceneral and of trianging I attre
Simon, Henry Business or Residence Address	(N) 1	0: 0: 7: 0	- 1 \		
Business of Residence Address	(Number and	Street, City, State, Zip Co	ode)		
c/o Eyetech Pharmaceuticals, Inc., 500	Seventh Avenue	e, 18 th Floor, New York,	NY 10018		
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Wicker, Damion					
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		
c/o Eyetech Pharmaceuticals, Inc., 500					
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	1				
Burns, Thomas					
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		
25 Agia Laguana Nigaal CA 02677					
25 Agia, Laguana Nigael, CA 92677 Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)		Belieffelal Owlier	DACCUITE Officer	_ Director	General and/or Managing Lattice
2 11.7 (21.31 11.11.11.11.11.11.11.11.11.11.11.11.11					
Schroder Ventures International Life S					
Business or Residence Address	(Number and	Street, City, State, Zip C	ode)		
22 Church Street, Hamilton, HM 11 Be	ermuda				
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Lakeview Eyetech, L.P.					
Business or Residence Address	(Number and	Street, City, State, Zip C	ode)		
		•	,		
c/o Prime Capital Investors LLC, 125 S					
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Tun Tune (East name 1116t, it metvious)					
Merrill Lynch KeCalp LP 1999					
Business or Residence Address	(Number and	Street, City, State, Zip C	ode)		
95 Greene St., Jersey City, NJ 07302					
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
I.D. M (DIICA) I. D.					
J.P. Morgan Partners (BHCA), L.P. Business or Residence Address	(Number and	Street, City, State, Zip C	ode)		
Business of Residence Fludiess	(rumber and	oneet, eny, state, zip e	ode)		
One Bush Street, San Francisco, CA 94	104				
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Biotech Growth N.V					
Business or Residence Address	(Number and	Street, City, State, Zip C	ode)		
	F 4 001 40				
One Cambridge Center, Cambridge, M Check Box(es) that Apply:		■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	□ Promoter	Denencial Owner	□ Executive Officer	□ Director	Ocheral and/or Managing Partner
Pfizer Ireland Pharmaceuticals		A			
Business or Residence Address	(Number and	Street, City, State, Zip C	ode)		
	Ireland				

Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if individual)								
O'Shaughnessy, Denis								
Business or Residence Address	(Number and	Street, City, State, Zip Cod	e)					
c/o Eyetech Pharmaceuticals, Inc., 500	Seventh Avenue	e, 18 th Floor, New York, N	Y 10018					
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if individual)								
Ural, Arda								
Business or Residence Address	(Number and	Street, City, State, Zip Cod	e)					
(T	ath The state of t							
c/o Eyetech Pharmaceuticals, Inc., 500	Seventh Avenue	, 18" Floor, New York, N	X 10018					
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if individual)								
Williams Charles								
Williams, Charles								
Business or Residence Address	(Number and	Street, City, State, Zip Cod	e)					
c/o Eyetech Pharmaceuticals, Inc., 500 Seventh Avenue, 18th Floor, New York, NY 10018								
Check Box(es) that Apply:					- C 1 1/ 1/ 1/ 1 D			
* * *	□ Promoter	☐ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner			
Full Name (Last name first, if individual)								
DaSilva, Loni								
	(Mumahan - :	Street City State 7:- C-						
Business or Residence Address	(Number and	Street, City, State, Zip Cod	e)					
c/o Eyetech Pharmaceuticals, Inc., 500	Seventh Avenue	e, 18th Floor, New York, N	Y 10018					

,	B. INFORMATION ABOUT OFFERING		
		Yes	No
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering? Answer also in Appendix, Column 2, if filing under ULOE.		•
2.	What is the minimum investment that will be accepted from any individual?	\$ <u>N/A</u>	
		Yes	No
3.	Does the offering permit joint ownership of a single unit?		
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.		
Full	Name (Last name first, if individual)		
None	e		
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)		
Nam	ne of Associated Broker or Dealer	<u> </u>	
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
_ [/ _ [] _ []	IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA} _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Full	name (Last name first, if individual)		
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)		
Nam	ne of Associated Broker or Dealer		
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
_ [/ _ [] _ [] _ []	IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [MÉ] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Full	Name (Last name first, if individual)		
Busi	ness or Residence Address (Number and Street, City, State, Zip Code)		
Nam	ne of Associated Broker or Dealer		
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
A] _ I] _ I] _ I] _	IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box pand indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	\$	\$
	Equity	\$ <u>25,000,002.30</u>	\$ <u>25,000,002.30</u>
	□ Common ■ Preferred		
	Convertible Securities (including warrants)	\$	\$
	Partnership Interests	\$	\$
	Other (Specify)	\$	\$
	Total	\$25,000,002.30	\$25,000,002.30
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	1	\$ <u>25,000,002.30</u>
	Non-accredited Investors		\$
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE		Ψ
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1. Type of offering	Type of Security	Dollar Amount Sold
	Rule 505		
	Regulation A		\$
	Rule 504		\$
	Total		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$
	Printing and Engraving Costs		\$
	Legal Fees	•	\$ <u>25,000</u>
	Accounting Fees		\$
	Engineering Fees.		\$
	Sales Commissions (specify finders' fees separately)		\$
	Other Expenses (identify)		\$
	Total		\$25,000

	C. OFFERING PRICE, NUMBER OF INVESTORS,	EXPENSES AN	ND USE OF PROCEEDS	·	
	b. Enter the difference between the aggregate offering price given in response to Part 1 and total expenses furnished in response to Part C – Question 4.a. This difference is "adjusted gross proceeds to the issuer."	s the		\$	<u>24,975,002,30</u>
5.	Indicate below the amount of the adjusted gross proceeds to the issuer used or propose for each of the purposes shown. If the amount for any purpose is not known, furnish a and check the box to the left of the estimate. The total of the payments listed must equaljusted gross proceeds to the issuer set forth in response to Part C – Question 4.b about 100 must be considered to the constant of the payments and the constant of the payments listed must equal to the payments are constant of the payments are constant.	an estimate ual the			
			Payments to Officers, Directors, & Affiliates		Payments To Others
	Salaries and fees	0	\$		\$
	Purchase of real estate	0	\$		\$
	Purchase, rental or leasing and installation of machinery and equipment		\$		\$
	Construction or leasing of plant buildings and facilities	0	\$		\$
	Acquisition of other business (including the value of securities involved in this offering				
	that may be used in exchange for the assets or securities of another issuer pursuant to merger)	a □	\$		\$
	Repayment of indebtedness		\$		\$
	Working capital and product development		\$		\$ <u>24,975,002.30</u>
	Other (specify):	0	\$		\$
		<u> </u>	\$		\$
	Column Totals	_	\$	_	\$ 24,975,002.30
	Total Payments Listed (column totals added)		■ \$ <u>.2</u>	4,975,002.	30
	D. FEDERAL SIGN.	ATURE			
		-			
an ı	issuer has duly caused this notice to be signed by the undersigned duly authorized persondertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, up-accredited investor pursuant to paragraph (b)(2) of Rule 502.				
Issu	er (Print or Type)		Date		
	etech Pharmaceuticals, Inc.		February 10	, 2003	

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)